pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Boehringer Ingelheim Corp

updated 5mo ago

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one.

community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval222 co-mentions · 111 sources
  • drugTRIJARDY XR96 co-mentions · 89 sources
  • tagSmall Molecule96 co-mentions · 95 sources
  • drugSYNJARDY35 co-mentions · 35 sources
  • drugempagliflozin26 co-mentions · 26 sources
  • drugJARDIANCE26 co-mentions · 26 sources
  • drugCYLTEZO24 co-mentions · 12 sources
  • drugHUMIRA24 co-mentions · 12 sources
pipeline
27
marketed
20
phase 3
0
catalysts ytd
3
approvals ytd
3
recalls ytd
0

Pipeline(27)

view full pipeline →
pipeline depth27 products
Marketed: 20Unknown: 7
20Marketed7Unknown
Marketed
(empagliflozin + linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed
(empagliflozin + linagliptin)
Type 2 Diabetes
Marketed
(empagliflozin + metformin hydrochloride ER)
Type 2 Diabetes
Marketed
(linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed
(olodaterol hydrochloride + tiotropium bromide)
Chronic Bronchitis
Marketed
CYLTEZO
Marketed
Combivent Respimat
Bronchospasm
Marketed
LINAGLIPTIN
Type 2 Diabetes
Marketed
Micardis HCT
Hypertension
Marketed
Ofev
Systemic Sclerosis (Scleroderma)
Marketed
SYNJARDY
Cardiovascular Risk Factors
Marketed
Spiriva
Bronchospasm

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Boehringer Ingelheim Corp jobs →

News

  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 1d ago
  • Their loss, our gain? Canada makes its case to Europe amid U.S. instability
    Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
    biospace · 2d ago
  • Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech
    → AbbVie and Boehringer Ingelheim’s Danish obesity partner Gubra is going with a co-CEO arrangement after the abrupt departure of Markus Rohrwild. Endpoints News just spoke with Rohrwild last month…
    endpoints · 6d ago
  • Drug price hikes in Germany could push US costs higher, study says
    The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.
    biopharma_dive · 7d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 8d ago
  • Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
    Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.
    biospace · 8d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 9d ago
  • Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
    The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…
    biospace · 9d ago
  • #AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
    Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like hea…
    endpoints · 9d ago
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
    biopharma_dive · 13d ago
view all news mentions →
identifiers
source
globaldata
top tags
Type 2 Diabetes5Cardiology4Pulmonology4COPD3NSCLC2
mentioned in
10news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?